{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:01:56Z","timestamp":1787508116403,"version":"build-2736575974"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0124205","type":"journal-article","created":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T13:56:44Z","timestamp":1430488604000},"page":"e0124205","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":74,"title":["Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic Review"],"prefix":"10.1371","volume":"10","author":[{"given":"Mohammed A.","family":"Omair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Alahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,5,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/BOR.0b013e32830c45ae","article-title":"T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis","volume":"20","author":"C Chizzolini","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"ref2","first-page":"1643","article-title":"The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma)","volume":"32","author":"JL Senecal","year":"2005","journal-title":"J Rheumatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0b013e3283310d57","article-title":"Disease-modifying treatment in systemic sclerosis: current status","volume":"21","author":"NP Quillinan","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.100361","article-title":"Biologic therapy for systemic sclerosis: a systematic review","volume":"38","author":"V Phumethum","year":"2011","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"AC Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1097\/00007890-199812270-00027","article-title":"Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function","volume":"66","author":"M Hueso","year":"1998","journal-title":"Transplantation"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/TP.0b013e3181e6ae0a","article-title":"Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway","volume":"90","author":"A Djamali","year":"2010","journal-title":"Transplantation"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/art.23634","article-title":"Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis","volume":"58","author":"J Rosenbloom","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"CE Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"BH Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2165\/0003495-200868170-00007","article-title":"Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection","volume":"68","author":"M Sanford","year":"2008","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1399-0012.2004.00318.x","article-title":"Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil","volume":"19","author":"W Arns","year":"2005","journal-title":"Clin Transplant"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-0012.2008.00892.x","article-title":"Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies","volume":"22","author":"S Bunnapradist","year":"2008","journal-title":"Clin Transplant"},{"issue":"Suppl 3","key":"ref14","first-page":"iii36","article-title":"Gastrointestinal complications: the most frequent internal complications of systemic sclerosis","volume":"48","author":"A Forbes","year":"2009","journal-title":"Rheumatology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3899\/jrheum.110826","article-title":"Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis","volume":"39","author":"MA Omair","year":"2012","journal-title":"J Rheumatol"},{"key":"ref16","first-page":"1117","article-title":"Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases","volume":"33","author":"SR Johnson","year":"2006","journal-title":"J Rheumatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"O Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref18","first-page":"143637","article-title":"Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis","volume":"2012","author":"A Tzouvelekis","year":"2012","journal-title":"Pulmo Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/rheumatology\/40.1.84","article-title":"Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma","volume":"40","author":"RJ Stratton","year":"2001","journal-title":"Rheumatology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3899\/jrheum.111229","article-title":"A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset","volume":"39","author":"FA Mendoza","year":"2012","journal-title":"J Rheumatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","article-title":"A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis","volume":"48","author":"CT Derk","year":"2009","journal-title":"Rheumatology"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10067-011-1823-1","article-title":"Effect of mycophenolate sodium in scleroderma-related interstitial lung disease","volume":"30","author":"CP Simeon-Aznar","year":"2011","journal-title":"Clin Rheumatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3899\/jrheum.090668","article-title":"Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis","volume":"37","author":"AL Herrick","year":"2010","journal-title":"J Rheumatol"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","article-title":"Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease","volume":"45","author":"SNC Liossis","year":"2006","journal-title":"Rheumatology"},{"key":"ref25","first-page":"287","article-title":"A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis","volume":"25","author":"M Vanthuyne","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease","volume":"133","author":"AJ Gerbino","year":"2008","journal-title":"CHEST"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2014A retrospective analysis","volume":"46","author":"SI Nihtyanova","year":"2007","journal-title":"Rheumatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","article-title":"Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease","volume":"102","author":"AC Zamora","year":"2008","journal-title":"Resp Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-010-1498-z","article-title":"Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease","volume":"29","author":"A Koutroumpas","year":"2010","journal-title":"Clin Rheumatol"},{"key":"ref30","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study","volume":"35","author":"A Berezne","year":"2008","journal-title":"J Rheumatol"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","article-title":"Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis","volume":"70","author":"EN Le","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study","volume":"191","author":"ST Panopoulos","year":"2013","journal-title":"Lung"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/rheumatology\/kel335","article-title":"Mycophenolate mofetil for interstitial lung disease in scleroderma","volume":"45","author":"SC Plastiras","year":"2006","journal-title":"Rheumatology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/rheumatology\/keq024","article-title":"Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?","volume":"49","author":"J Busquets","year":"2010","journal-title":"Rheumatology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.arbr.2011.06.013","article-title":"Efficacy of mycophenolate associated with methotrexate as a maintenance treatment for systemic sclerosis-associated interstitial lung disease","volume":"47","author":"JA Gonzalez-Nieto","year":"2011","journal-title":"Arch Bronconeumol"},{"key":"ref36","first-page":"1735","article-title":"Effectiveness and safety of mycophenolate mofetil in the treatment of interstitial lung disease in patients with systemic sclerosis","volume":"60","author":"G Cuomo","year":"2009","journal-title":"Arthritis and Rheumatism Conference: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR\/ARHP 09 Atlanta, GA United States"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","article-title":"Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects","volume":"337","author":"LA Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3899\/jrheum.080611","article-title":"Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil","volume":"36","author":"A Gulamhusein","year":"2009","journal-title":"J Rheumatol"},{"key":"ref39","first-page":"41","article-title":"Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies","volume":"139","author":"C Bandelier","year":"2009","journal-title":"Swiss Med Wkly"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00296-009-0879-6","article-title":"Early onset neutropenia after mycophenolate mofetil in systemic sclerosis","volume":"29","author":"G Cuomo","year":"2009","journal-title":"Rheumatol Int"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"M Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"JJ Swigris","year":"2006","journal-title":"CHEST"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.arbr.2011.06.013","article-title":"Efficacy of Mycophenolate Associated with Methotrexate as a Maintenance Treatment for Systemic Sclerosis-Associated Interstitial Lung Disease. [Spanish]","volume":"47","author":"JA Gonzalez-Nieto","year":"2011","journal-title":"Arch Bronconeumol"},{"key":"ref44","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing","volume":"26","author":"TA Medsger Jr.","year":"1999","journal-title":"J Rheumatol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00002018-200124090-00002","article-title":"Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management","volume":"24","author":"M Behrend","year":"2001","journal-title":"Drug Saf"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-0012.2008.00892.x","article-title":"Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies","volume":"22","author":"S Bunnapradist","year":"2008","journal-title":"Clin Transplant"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument","volume":"61","author":"D Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"FA Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"MA Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"M Zeher","year":"2011","journal-title":"Lupus"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.106.117051","article-title":"In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil","volume":"321","author":"N Roos","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/FTD.0b013e3181e44260","article-title":"Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function","volume":"32","author":"DT Petrova","year":"2010","journal-title":"Ther Drug Monit"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1523-1755.2000.00140.x","article-title":"Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney","volume":"58","author":"C Badid","year":"2000","journal-title":"Kidney Int"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.100361","article-title":"Biologic therapy for systemic sclerosis: a systematic review","volume":"38","author":"V Phumethum","year":"2011","journal-title":"J Rheumatol"},{"key":"ref55","first-page":"S55","article-title":"Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis","volume":"30","author":"MA Omair","year":"2012","journal-title":"Clin Exp Rheumatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0124205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T08:06:47Z","timestamp":1566634007000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0124205"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0124205","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,1]]}}}